relmacabtagene autoleucel injection，瑞基奥仑赛注射液

This product is used to treat:

Relapsed or refractory large B-cell lymphoma in adult patients after second-line or higher systemic treatment, including diffuse large B-cell lymphoma not otherwise specified, diffuse large B-cell lymphoma transformed from follicular lymphoma, grade 3b follicular lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangement (double hit/triple hit lymphoma). This indication is conditionally approved for marketing, and more efficacy and safety data are to be provided by post-marketing studies.

Adult refractory or relapsed follicular lymphoma within 24 months after second-line or higher systemic treatment, including follicular lymphoma with histological grades 1, 2, and 3a.

This indication is conditionally approved for marketing, and longer-term efficacy data are to be provided by post-marketing studies.

Combined medication

A reasonable combination of drugs can enhance the efficacy or reduce adverse drug reactions. Conversely, it can lead to reduced efficacy or increased toxicity. Some abnormal reactions may also occur, interfere with treatment, and aggravate the condition. Therefore, when patients take medication, they should not use it in combination with other drugs privately to avoid drug interactions.